Original Article

Retrospective analysis of long-term survival after combination treatment with gemcitabine, oxaliplatin and paclitaxel in patients with refractory or relapsed testicular cancers


  • İsmail Ertürk
  • Birol Yıldız
  • Nuri Karadurmuş
  • Betül Tosun
  • Ramazan Esen
  • Ramazan Acar
  • Murat Urkan
  • Gökhan Erdem

Received Date: 13.06.2018 Accepted Date: 20.09.2018 Gulhane Med J 2018;60(4):145-150


Testicular tumors are one of the most common malignancies in males, between 15 and 35 years of age. Testicular cancer patients are treated with the combination of gemcitabine, oxaliplatin and paclitaxel (GOP) in relapsed and refractory disease, but the literature about the GOP treatment is limited. We aimed to demonstrate the real-life data of progressive testicular cancer patients who received GOP treatment.


Medical records of 17 patients who received GOP treatment at the Gulhane Training and Research Hospital were reviewed retrospectively. Overall response rate (ORR), overall survival (OS) rate and progression-free survival (PFS) of the patients were evaluated.


Overall response was obtained in 58.8% (n=10), and a complete response was achieved in 11.2% (n=2) of the cases. OS time was 14.2 months and the OS rate in the first year was 73.1%. The PFS time was 7.6 months. In most of the patients, thrombocytopenia, anemia and leukopenia were observed during GOP treatment.


GOP is a safe and effective treatment option for relapsed refractory testicular cancer patients with an acceptable ORR, OS and PFS time. Additionally, GOP treatment was associated with cognitive side effects in patients.

Keywords: Gemcitabine, paclitaxel, oxaliplatin, testicular cancer